Welcome to LookChem.com Sign In|Join Free

CAS

  • or

1572510-42-9

JNJ-632 is a potent and selective inhibitor of the protein tyrosine phosphatase 1B (PTP1B) enzyme, which is involved in the regulation of insulin signaling and metabolism. Its ability to inhibit PTP1B endows JNJ-632 with potential therapeutic applications in the treatment of type 2 diabetes and associated metabolic disorders.
Used in Pharmaceutical Industry:
JNJ-632 is used as a therapeutic agent for the treatment of type 2 diabetes and related metabolic disorders due to its ability to improve insulin sensitivity and glucose tolerance. It also has the potential to reduce body weight and improve lipid metabolism in animal models of obesity and diabetes.
Used in Metabolic Research:
JNJ-632 is used as a research tool to study the role of PTP1B in insulin signaling and metabolism. Its mechanism of action and promising preclinical data make JNJ-632 a potential candidate for further development as a novel therapy for metabolic diseases, contributing to the advancement of understanding and treatment of metabolic disorders.

1572510-42-9 Suppliers

Post Buying Request

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

  • N-(4-fluoro-3-methylphenyl)-3-{[(3S)-oxolan-3-yl]sulfamoyl}benzamide

    Cas No: 1572510-42-9

  • USD $ 1.9-2.9 / Gram

  • 100 Gram

  • 1000 Metric Ton/Month

  • Chemlyte Solutions
  • Contact Supplier
  • 1572510-42-9 Structure

  • Basic information

    1. Product Name: JNJ-632
    2. Synonyms: JNJ-632
    3. CAS NO:1572510-42-9
    4. Molecular Formula: C18H19FN2O4S
    5. Molecular Weight: 378.42
    6. EINECS: -0
    7. Product Categories: API
    8. Mol File: 1572510-42-9.mol

  • Chemical Properties

    1. Melting Point: N/A
    2. Boiling Point: N/A
    3. Flash Point: N/A
    4. Appearance: /
    5. Density: 1.39±0.1 g/cm3(Predicted)
    6. Refractive Index: N/A
    7. Storage Temp.: N/A
    8. Solubility: N/A
    9. PKA: 10.37±0.20(Predicted)
    10. CAS DataBase Reference: JNJ-632(CAS DataBase Reference)
    11. NIST Chemistry Reference: JNJ-632(1572510-42-9)
    12. EPA Substance Registry System: JNJ-632(1572510-42-9)

  • Safety Data

    1. Hazard Codes: N/A
    2. Statements: N/A
    3. Safety Statements: N/A
    4. WGK Germany:
    5. RTECS:
    6. HazardClass: N/A
    7. PackingGroup: N/A
    8. Hazardous Substances Data: 1572510-42-9(Hazardous Substances Data)

1572510-42-9 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 1572510-42-9 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,5,7,2,5,1 and 0 respectively; the second part has 2 digits, 4 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 1572510-42:
(9*1)+(8*5)+(7*7)+(6*2)+(5*5)+(4*1)+(3*0)+(2*4)+(1*2)=149
149 % 10 = 9
So 1572510-42-9 is a valid CAS Registry Number.

1572510-42-9Downstream Products

1572510-42-9Relevant articles and documents

Synthesis and Evaluation of N-Phenyl-3-sulfamoyl-benzamide Derivatives as Capsid Assembly Modulators Inhibiting Hepatitis B Virus (HBV)

Vandyck, Koen,Rombouts, Geert,Stoops, Bart,Tahri, Abdellah,Vos, Ann,Verschueren, Wim,Wu, Yiming,Yang, Jingmei,Hou, Fuliang,Huang, Bing,Vergauwen, Karen,Dehertogh, Pascale,Berke, Jan Martin,Raboisson, Pierre

, p. 6247 - 6260 (2018/06/25)

Small molecule induced hepatitis B virus (HBV) capsid assembly modulation is considered an attractive approach for new antiviral therapies against HBV. Here we describe efforts toward the discovery of a HBV capsid assembly modulator in a hit-to-lead optimization, resulting in JNJ-632, a tool compound used to further profile the mode of action. Administration of JNJ-632 (54) in HBV genotype D infected chimeric mice resulted in a 2.77 log reduction of the HBV DNA viral load.

SULFAMOYL-ARYLAMIDES AND THE USE THEREOF AS MEDICAMENTS FOR THE TREATMENT OF HEPATITIS B

-

Page/Page column 54, (2014/03/25)

Inhibitors of HBV replication of Formula (I) including stereochemically isomeric forms, and salts, hydrates, solvates thereof, wherein B, R1, R2 and R4 have the meaning as defined herein. The present invention also relates to processes for preparing said compounds, pharmaceutical compositions containing them and their use, alone or in combination with other HBV inhibitors, in HBV therapy.

SULFAMOYL-ARYLAMIDES AND THE USE THEREOF AS MEDICAMENTS FOR THE TREATMENT OF HEPATITIS B

-

Page/Page column 54, (2014/03/25)

Inhibitors of HBV replication of Formula (I) including stereochemically isomeric forms, and salts, hydrates, solvates thereof, wherein B, R1, R2 and R4 have the meaning as defined herein. The present invention also relates to pharmaceutical compositions containing these inhibitors and to their use, alone or in combination with other HBV inhibitors, in HBV therapy.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 1572510-42-9